Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Angiogenesis is now recognized as a crucial process in tumor development. Copper appears to act as an essential cofactor for several angiogenic growth factors, and both copper metabolism and ceruloplasmin expression are upregulated in many tumors. The role of copper chelators has been investigated in animal models with promising results. New therapies for Wilson's disease (a disease of copper accumulation) have enabled clinical trials of copper chelation to be undertaken. Here we discuss the evidence for a role of copper in angiogenesis and possible mechanisms of action of anticopper agents.

Original publication

DOI

10.3727/0965040042707952

Type

Journal article

Journal

Oncol Res

Publication Date

2004

Volume

14

Pages

529 - 539

Keywords

Animals, Chelating Agents, Clinical Trials as Topic, Copper, Disease Models, Animal, Hepatolenticular Degeneration, Humans, Neoplasms, Neovascularization, Pathologic